Company Insights

RLMD supplier relationships

Explore interactive graphBrowse insights index
RLMD supplier relationship map

Relmada Therapeutics (RLMD): Partner Map, Capital Partners and Operational Constraints for Suppliers

Relmada is a clinical-stage biotech that acquires and licenses CNS and urology assets, advances them through clinical development using outsourced partners, and funds operations primarily through equity raises and milestone-driven licensing economics. The company currently has zero product revenue and monetizes value by progressing candidates to de-risking clinical data and capturing upside through licensing, milestone payments and potential commercialization rights. For a quick overview of third‑party exposure and partner signals, visit https://nullexposure.com/.

What the business model looks like in practice

Relmada’s operating model is straightforward: asset accumulation + outsourced development + capital markets funding. The company buys or licenses molecules (for example, sepranolone and NDV‑01), contracts CROs and contract manufacturers to run trials and produce material, and repeatedly turns to investment banks and private placements to raise cash. That structure creates two persistent supplier dynamics: high dependence on third‑party service providers (CROs, CMOs) and a funding profile concentrated in equity-led transactions and milestone contingent payments.

  • Contracting posture: Licensing and acquisition sit at the center of the go‑to‑market strategy — Relmada holds exclusive licenses on several assets while also taking on vendor relationships for trial execution and manufacturing.
  • Concentration and criticality: Clinical progress is highly dependent on a handful of license agreements and outsourced manufacturers/CROs, which the company itself identifies as material to its development program.
  • Maturity: Programs are clinical-stage with no commercial revenue to date, so supplier relationships are mission‑critical rather than auxiliary.
  • Funding posture: The company consistently pursues equity offerings and private placements, and it commits meaningful upfront payments (low‑single to mid‑single digit millions) with substantial contingent milestone exposure (up to hundreds of millions).

If you evaluate supplier or counterparty risk for Relmada, these are the baseline signals to model. For a structured feed of supplier relationships and audit trails, see https://nullexposure.com/.

The partner map — who Relmada is working with (and what they do)

Below are every partner referenced in the collected results, with concise, investor‑facing descriptions and source citations.

Asarina Pharma AB

Relmada acquired sepranolone (isoallopregnanolone) from Asarina, an investigational injection intended to target compulsive behaviors and PWS (Prader‑Willi syndrome), and paid a portion of the purchase consideration earlier in 2025. This acquisition is positioned as a near‑term program addition to Relmada’s CNS pipeline. According to a PR and news coverage in FY2025, Relmada bought sepranolone from Asarina (PRaderWillinNews, March 2026) and RTT News also noted the February 2025 acquisition in coverage of lower‑urinary‑tract/oncology ambitions (RTT News, FY2025).

Trigone Pharma, Ltd.

Relmada signed an Exclusive License Agreement with Trigone for NDV‑01 in March 2025; filings indicate an upfront payment ($3.5 million) plus issuance of 3,017,420 shares (representing roughly 10% of outstanding shares at the time) for global rights excluding Israel, India and South Africa. This transaction positions Trigone as a primary licensor for Relmada’s urology program and structurally increases counterparty and dilution risk tied to the NDV‑01 asset. The licensing deal and terms are referenced in company filings and was reported in FY2025 news coverage (RTT News, March 2025; company filings, FY2025).

Jefferies

Jefferies acted as a joint book‑running manager on Relmada’s underwritten offering and is listed as a placement agent on subsequent private placements; the bank is a principal capital markets partner for transaction execution. GlobeNewswire documented Jefferies’ role in the November 4, 2025 offering, and later coverage confirmed Jefferies’ placement agent status for a March 2026 private placement (GlobeNewswire, Nov 4, 2025; TradingView, FY2026).

Piper Sandler

Piper Sandler participated as a placement agent on Relmada’s private placement alongside other banks; this marks Piper Sandler as part of Relmada’s go‑to group for equity financing and syndication. TradingView reported Piper Sandler’s placement agent role in the March 2026 private placement announcement (TradingView, FY2026).

Leerink Partners

Leerink Partners served as a joint book‑runner and placement agent on Relmada’s public and private financings, reinforcing the company’s reliance on specialist healthcare capital markets desks for liquidity events. GlobeNewswire (Nov 4, 2025) and TradingView (FY2026) list Leerink’s participation.

Mizuho

Mizuho served as a book‑runner/placement agent alongside Jefferies and others in the November 2025 and March 2026 financing activity; the bank is part of the transaction syndicate that supplies capital markets access. GlobeNewswire and subsequent trading‑news coverage reference Mizuho’s role (GlobeNewswire, Nov 4, 2025; TradingView, FY2026).

Arbormentis

Relmada acquired psilocybin and derivative programs from Arbormentis, adding psychedelic‑adjacent neurodegenerative assets to its pipeline; the deal was highlighted in earlier coverage when Relmada’s depression program failed to outperform placebo. FierceBiotech reported on the Arbormentis acquisition and contextualized it within Relmada’s shifting pipeline strategy (FierceBiotech, FY2022).

LifeSci Advisors

LifeSci Advisors is listed as an investor relations contact for Relmada’s NDV‑01 Phase 2 data presentation at a urologic oncology meeting, indicating a retained IR/service relationship for investor communications and data dissemination. GlobeNewswire’s December 3, 2025 press release lists LifeSci as Relmada’s investor contact (GlobeNewswire, Dec 3, 2025).

What the relationships imply for suppliers and investors

  • Large dependency on licensed assets: Multiple exclusive licenses and acquisitions mean suppliers supporting development (CMOs, CROs, clinical sites) are directly tied to whether assets progress to later‑stage trials. The Trigone license explicitly demonstrates Relmada’s willingness to pay upfront cash and equity for global rights.
  • Funding concentrated in equity markets: Relmada runs underwritten offerings and private placements (reported $100M underwritten offering in Nov 2025 and a $160M private placement in March 2026), creating recurring counterparty exposure to placement agents and underwriters for liquidity events (GlobeNewswire, Nov 4, 2025; TradingView, FY2026). Supplier payment risk is mitigated by active capital raises but balanced against dilution.
  • Material third‑party reliance is explicit: Company disclosures call out manufacturers and CROs as materially important to timelines and regulatory compliance; that elevates operational concentration risk for suppliers providing those services.
  • Spend profile is mixed but meaningful: Documented upfront payments are in the low‑millions (Asarina, NDV‑01) while milestone exposure can reach into the hundreds of millions, which aligns incentives but also concentrates upside in future success events.

If you are evaluating an engagement with Relmada — as a CMO, CRO, or financial counterparty — price for the reality that payment and work continuity hinge on frequent capital raises and successful clinical readouts, and model both transaction fees and milestone upside accordingly. For a centralized view of supplier exposure and to monitor new relationships, visit https://nullexposure.com/.

Bottom line and next steps

Relmada is an acquisition‑and‑license‑led small biotech that outsources execution and repeatedly taps capital markets to fund development. Key supplier risks are concentration, materiality of outsourced services, and dilution through equity compensation in licensing deals. Evaluate counterparty terms with those dynamics in mind and require contractual protections that reflect the company’s capital and clinical risk profile.

Explore more supplier intelligence and relationship histories at https://nullexposure.com/ to support diligence or vendor underwriting decisions.